Evelyn Lomasney
Allergy & Immunology · High Point, NCNPI 1578869624
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 358 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,252, more than ten times the $234 reported in 2022.
Across 358 payments — averaging $23.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Sanofi$845
- GSK$812
- Novartis$714
- Amgen$698
- plus $2K from 27 others
What the payments were for
- Consulting fees$1081%
- Food & beverage$8,22898%
- Education$741%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 66 | $1,785 |
| Regeneron Healthcare Solutions, Inc. | 42 | $1,227 |
| Sanofi | 38 | $845 |
| GSK | 52 | $812 |
| Novartis | 32 | $714 |
| Amgen(2 entities) | 31 | $698 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $373 |
| AbbVie | 14 | $361 |
| Biocryst US Sales Co., LLC | 7 | $178 |
| Genentech USA, Inc. | 7 | $151 |
| CSL Behring | 5 | $126 |
| Pfizer | 1 | $125 |
| ADMA Biomanufacturing LLC | 5 | $108 |
| Galderma Laboratories, L.p. | 5 | $87 |
| LEO Pharma Inc. | 5 | $82 |
| Kaleo, Inc. | 5 | $77 |
| Regeneron | 2 | $73 |
| Grifols USA, LLC | 4 | $70 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $65 |
| Philips North America LLC | 3 | $65 |
| Octapharma USA, Inc. | 3 | $56 |
| Incyte Corporation | 2 | $52 |
| Hikma Pharmaceuticals USA | 3 | $48 |
| Ionis Pharmaceuticals, Inc. | 2 | $44 |
| Pharming Healthcare, Inc. | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
| Merck | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| Optinose US, Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $18 |
| Organon | 1 | $17 |
| Cycle Pharmaceuticals Inc | 1 | $17 |
| Hospira, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,409 in reported general payments places this provider in the 60th percentile of 140 allergy & immunology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TezspireTezepelumab-Ekko | 20 | $87,443 |
| Dupixent SyringeDupilumab | 18 | $73,278 |
| XolairOmalizumab | 17 | $59,593 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $28,789 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 42 | $28,368 |
| Spiriva RespimatTiotropium Bromide | 23 | $14,368 |
| Epinephrine | 35 | $6,706 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $6,535 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $5,320 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $4,407 |
| Ipratropium Bromide | 148 | $3,829 |
| Azelastine Hcl | 104 | $3,682 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 13 | $3,128 |
| Wixela InhubFluticasone Propion/Salmeterol | 12 | $1,980 |
| Montelukast Sodium | 154 | $1,706 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $1,785 | $120,21878 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $812 | $35,32456 claims |
| Boehringer IngelheimSpiriva Respimat | $18 | $14,36823 claims |
| Hikma Pharmaceuticals USAEpinephrine | $48 | $6,70635 claims |
| Cycle Pharmaceuticals IncCromolyn Sodium | $17 | $41925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 140 allergy & immunology providers in North Carolina.
Other allergy & immunology in High Point
- Jose BardelasHigh Point$10K
- Maeve OconnorCharlotte$2.2M
- Joel HartmanWinston Salem$749K
- Cristine RadojicicDurham$558K
- Scott ComminsChapel Hill$555K
- William McCannAsheville$486K
- Aerik WilliamsSalisbury$298K
- Karen DunnRaleigh$258K
- Roopen PatelCharlotte$257K
- Jonathan RomeoRaleigh$230K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.